Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
This page provides a historical news archive for Singular Genomics Systems, Inc., which previously traded on Nasdaq under the symbol OMIC. The company describes itself as a life science technology company developing next-generation sequencing (NGS) and multiomics technologies, including the G4® Sequencing Platform and the G4X™ Spatial Sequencer. Its news releases document product milestones, spatial biology data presentations, corporate transactions and capital markets developments.
Readers can review announcements about the G4 Sequencing Platform, which Singular Genomics characterizes as a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. News items also cover progress on the G4X Spatial Sequencer, described as a system under development that will apply the company’s proprietary sequencing technology as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue with spatial context.
The archive includes updates on spatial multiomics performance in FFPE tissues, 3D multi-omic reconstruction, Direct-Seq demonstrations for T- and B-cell receptor sequencing in tissue, and the company’s Spatial Technology Access Services program. In addition, corporate news covers events such as a 1-for-30 reverse stock split to address Nasdaq’s minimum bid price requirement, the receipt of acquisition proposals, the definitive merger agreement with an affiliate of Deerfield Management Company, L.P., and the closing of the Deerfield acquisition after stockholder approval.
Because Singular Genomics has stated that it now operates as a private company and has requested delisting from Nasdaq, the OMIC news feed serves as a record of its public-company history, technology development updates and key strategic decisions during its time as a listed issuer.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) has established a scientific advisory board (SAB) to enhance its product offerings and R&D pipeline. The SAB features distinguished experts, including Eli Glezer, Ph.D., as Chair, highlighting expertise in DNA sequencing and oncology. Notable members include David L. Barker, Ph.D., Lawrence Fong, M.D., and Elaine Mardis, Ph.D. The board will contribute to the advancement of Singular’s G4 sequencing system and the development of the innovative PX platform for spatial biology, aiming to accelerate genomics and improve clinical utility.
Singular Genomics Systems will disclose its Q1 2022 financial results on May 10, 2022, after market close. A conference call for management's discussion of results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. The company focuses on next-generation sequencing and multiomics technologies, aiming to enhance research and clinical applications. Singular's products, including the G4 and the upcoming PX, support its mission to advance genomics in science and medicine.
Singular Genomics Systems, Inc. (NASDAQ: OMIC) reported its Q4 and FY 2021 results, highlighting a net loss of $19.8 million for Q4 and $98.8 million for the full year. Operating expenses surged to $19.7 million in Q4 from $7.6 million YoY, driven by headcount growth and G4 product launch investments. The company initiated its G4 commercial launch, secured initial orders, and demonstrated industry-leading sequencing accuracy of ~99.8%. Cash and equivalents were approximately $339.2 million as of December 31, 2021.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will present virtually at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 11:10 a.m. PT / 2:10 p.m. ET. The management team will participate in a fireside chat, inviting investors to access live and recorded webcasts via the company's investor relations website. Singular Genomics focuses on next-generation sequencing (NGS) and multiomics technologies, with products aimed at enhancing research and clinical applications. Their G4 and PX instruments target significant advancements in genomics and proteomics.
Singular Genomics Systems announced a partnership with QIAGEN to validate its QIAseq DNA and RNA Library Prep Kits with the G4 sequencing platform. This collaboration aims to enhance customer workflows, providing a plug-and-play solution for integrating G4 into existing NGS systems. Both companies emphasize their commitment to advancing genomic applications in research and healthcare. The QIAseq portfolio is recognized for its effectiveness in detecting genomic changes, positioning Singular to strengthen its offerings in the genomics market.
Singular Genomics Systems (NASDAQ: OMIC) has partnered with Agilent Technologies to enhance its next-generation sequencing (NGS) capabilities. The collaboration aims to validate Agilent's SureSelect target enrichment products with Singular's G4 sequencing platform. This partnership is designed to provide researchers with more streamlined and effective targeted sequencing solutions. Agilent's extensive experience and technologies complement Singular's innovative approaches in genomics, potentially broadening their market reach.
Singular Genomics Systems (NASDAQ: OMIC) announced a collaboration with Roche to integrate KAPA Library Preparation Kits with its G4 sequencing platform. This partnership aims to enhance next-generation sequencing (NGS) workflows, providing customers with efficient and high-quality library prep solutions. Jorge Velarde, Senior VP at Singular Genomics, emphasized the significance of this collaboration for offering seamless integration into existing processes. Roche's advanced technologies will also broaden access to its library prep kits for Singular Genomics users, reinforcing commitment to innovation in genomics.
Singular Genomics Systems, Inc. will report its fourth quarter and full year 2021 financial results on March 2, 2022, after market close. Management will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The company focuses on next-generation sequencing and multiomics technologies, enhancing research and clinical capabilities. Their foundational product, the Singular Sequencing Engine, underpins two key developments: the G4 for NGS and the PX, integrating single cell and spatial analysis with genomics and proteomics.
Singular Genomics Systems (Nasdaq: OMIC) announced a partnership with Dovetail Genomics to enhance its proximity ligation kit portfolio, integrating Dovetail's technology with the G4 sequencing platform. This collaboration aims to enable a comprehensive understanding of 3-D genome architecture, crucial for gene expression regulation. Dovetail's robust genomic solutions will allow Singular Genomics customers to achieve advanced insights in genomics, facilitating improvements in precision medicine and life sciences research.
Singular Genomics Systems has announced a partnership with New England Biolabs (NEB) to validate NEBNext kits with the G4 sequencing platform. This collaboration aims to enhance the accuracy and efficiency of next-generation sequencing (NGS)/b) workflows for researchers. NEBNext kits are recognized for their quality in DNA and RNA sample preparation, promising improved yields and diversity. The partnership is designed to offer high-quality, established workflows, benefiting customers looking to integrate new technologies seamlessly.